Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-12-12 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
董事会薪酬与考核委员会工作细则（2023年12月）
Governance Information Classification · 95% confidence The document is titled '董事会薪酬与考核委员会工作细则' which translates to 'Board Remuneration and Assessment Committee Working Rules'. It details the structure, responsibilities, procedures, and rules of the board's remuneration and assessment committee. The content focuses on governance practices related to board and senior management compensation and evaluation. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, and no meeting materials. The document is a governance-related internal rules document outlining committee duties and procedures. Therefore, it fits best under Governance Information (CGR). The document length is 3409 characters, which is not a brief announcement but a full set of governance rules, supporting the CGR classification.
2023-12-12 Chinese
关于JK07境外临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Biotherapeutics regarding the progress of the JK07 drug's overseas clinical trials. It provides updates on regulatory approvals and clinical trial phases but does not contain financial statements, management discussion, or detailed financial data. The document length is short (1708 characters) and it is an announcement of clinical trial progress rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and compliance with disclosure obligations.
2023-11-22 Chinese
关于使用部分闲置募集资金现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds for cash management. It details the approval by the board, the amounts involved, the types of financial products purchased (large certificates of deposit), risk control measures, and the impact on the company. It references previous announcements and regulatory filings but does not contain financial statements or comprehensive financial data. The document length is 3545 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on updates about cash management activities related to raised funds, which aligns with capital/financing updates. Therefore, the document is best classified as a Capital/Financing Update (CAP).
2023-11-22 Chinese
关于参加2023年深圳辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor online collective reception day event, where company executives will interact with investors regarding company performance, governance, strategy, and operations. It is a public notice of an upcoming event rather than a report or detailed financial disclosure. The document is short (504 characters) and does not contain financial statements or detailed analysis. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is an announcement related to investor relations and communication. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-11-08 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "深圳信立泰药业股份有限公司2023 年第三季度报告" which translates to "Shenzhen Salubris Pharmaceuticals Co., Ltd. 2023 Third Quarter Report." It contains detailed financial data including income, profit, cash flow, balance sheet items, and explanations of changes in accounting policies. The document covers a period shorter than a full fiscal year (the third quarter of 2023) and includes substantive financial statements and analysis. It is not a brief announcement or a certification but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-10-30 Chinese
关于沙库巴曲缬沙坦钠片获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the receipt of a drug registration certificate for a specific pharmaceutical product. It includes details about the drug, regulatory approval, and a cautionary note to investors. The document is short (816 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial data, management changes, or voting results. It is not a report publication announcement since it does not mention the release of a report. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval.
2023-10-17 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.